AR115007A1 - Derivados de triazolona o sales de los mismos y composiciones farmacéuticas que comprenden los mismos - Google Patents

Derivados de triazolona o sales de los mismos y composiciones farmacéuticas que comprenden los mismos

Info

Publication number
AR115007A1
AR115007A1 ARP190100713A ARP190100713A AR115007A1 AR 115007 A1 AR115007 A1 AR 115007A1 AR P190100713 A ARP190100713 A AR P190100713A AR P190100713 A ARP190100713 A AR P190100713A AR 115007 A1 AR115007 A1 AR 115007A1
Authority
AR
Argentina
Prior art keywords
triazolone
derivatives
salts
same
pharmaceutical compositions
Prior art date
Application number
ARP190100713A
Other languages
English (en)
Spanish (es)
Inventor
Eui Chul Lee
Na Ry Ha
Mi Kyeong Ju
Tae Wang Kim
Hyun Ho Choi
So Young Kim
Dong Hoon Kim
Sol Park
Su Bin Choi
Eun Kyung Kim
Hee Jae Tak
Tae Dong Han
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of AR115007A1 publication Critical patent/AR115007A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ARP190100713A 2018-03-21 2019-03-21 Derivados de triazolona o sales de los mismos y composiciones farmacéuticas que comprenden los mismos AR115007A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020180032548A KR20190110736A (ko) 2018-03-21 2018-03-21 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물

Publications (1)

Publication Number Publication Date
AR115007A1 true AR115007A1 (es) 2020-11-18

Family

ID=67986894

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190100713A AR115007A1 (es) 2018-03-21 2019-03-21 Derivados de triazolona o sales de los mismos y composiciones farmacéuticas que comprenden los mismos

Country Status (10)

Country Link
US (2) US10995086B2 (cg-RX-API-DMAC7.html)
EP (1) EP3768675B1 (cg-RX-API-DMAC7.html)
JP (2) JP7383627B2 (cg-RX-API-DMAC7.html)
KR (2) KR20190110736A (cg-RX-API-DMAC7.html)
CN (1) CN111886233B (cg-RX-API-DMAC7.html)
AR (1) AR115007A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019237344B2 (cg-RX-API-DMAC7.html)
CA (1) CA3093057A1 (cg-RX-API-DMAC7.html)
TW (1) TWI803600B (cg-RX-API-DMAC7.html)
WO (1) WO2019180646A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190110736A (ko) * 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110740A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20200004036A (ko) * 2018-07-03 2020-01-13 주식회사유한양행 (e)-(2-(클로로메틸)-3-플루오로알릴)카바메이트 유도체의 제조방법
TWI835945B (zh) 2018-12-14 2024-03-21 南韓商柳韓洋行股份有限公司 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
TW202039486A (zh) 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
AU2020206477B2 (en) 2019-01-11 2022-11-10 Transthera Sciences (Nanjing), Inc. Haloallylamine compounds and application thereof
KR20220145981A (ko) * 2021-04-22 2022-11-01 주식회사유한양행 트리아졸론, 테트라졸론, 및 이미다졸론, 또는 그의 염, 및 그를 포함하는 제약 조성물

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2725148A1 (de) 1977-06-03 1978-12-14 Hoechst Ag 1-aryl-4-alkyl-1,2,4-triazol-5-one und verfahren zu ihrer herstellung
US20050096360A1 (en) 2003-08-08 2005-05-05 Salter-Cid Luisa M. Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment of diseases
KR100572996B1 (ko) 2003-08-12 2006-04-25 한국화학연구원 불소화 비닐 에테르 측쇄기를 갖는 아졸계 살균제 화합물및 그의 제조방법
WO2005082343A2 (en) 2004-02-25 2005-09-09 La Jolla Pharmaceutical Company Amines and amides for the treatment of diseases
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US20070293548A1 (en) 2006-03-31 2007-12-20 Wang Eric Y Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
EP2139333A4 (en) * 2007-03-28 2010-11-10 Merck Sharp & Dohme SUBSTITUTED PYRID- [3,2-E] - [1,2,4] -TRIAZOL- [4,3-C] -PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS
MX2009009920A (es) * 2007-03-29 2009-10-19 Hoffmann La Roche Inhibidores no nucleosidos de transcriptasa inversa.
GB0722075D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
US8426587B2 (en) 2007-11-21 2013-04-23 Pharmaxis Ltd. Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor
WO2010096722A1 (en) 2009-02-20 2010-08-26 Takeda Pharmaceutical Company Limited 3-oxo-2, 3-dihydro- [1,2, 4] triazolo [4, 3-a]pyridines as soluble epoxide hydrolase (seh) inhibitors
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2871793C (en) 2012-05-02 2020-09-15 Pharmaxis Ltd. Substituted 3-haloallylamine inhibitors of ssao and uses thereof
CN105143210A (zh) * 2013-04-25 2015-12-09 柳韩洋行 新的三唑酮衍生物或其盐以及含有其的药物组合物
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016092375A1 (en) * 2014-12-11 2016-06-16 Zenith Epigenetics Corp. Substituted heterocycles as bromodomain inhibitors
WO2016101119A1 (en) 2014-12-23 2016-06-30 Merck Sharp & Dohme Corp. Fused heteroaryl derivatives as orexin receptor antagonists
TW201722958A (zh) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產(第二)有限公司 化學化合物
SG11201806700RA (en) 2016-02-12 2018-09-27 Pharmaxis Ltd Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof
EP3452469A1 (en) 2016-05-03 2019-03-13 Bayer Pharma Aktiengesellschaft Fluoroalkyl-substituted aryltriazole derivatives and uses thereof
WO2018027892A1 (en) 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
CA3041169A1 (en) 2016-10-19 2018-04-26 Boehringer Ingelheim International Gmbh Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
CN110709385A (zh) 2017-03-02 2020-01-17 法玛西斯有限公司 赖氨酰氧化酶的卤代烯丙胺吡唑衍生物抑制剂及其用途
WO2018196677A1 (zh) 2017-04-28 2018-11-01 四川科伦博泰生物医药股份有限公司 氟代烯丙胺衍生物及其用途
FI3626699T3 (fi) 2017-06-20 2023-08-15 Shandong Danhong Pharmaceutical Co Ltd Ssao:n estäjä
CN109810041B (zh) 2017-11-21 2023-08-15 药捷安康(南京)科技股份有限公司 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
CN109988109B (zh) 2017-12-29 2020-12-29 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其用途
KR20190110740A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110736A (ko) * 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN110938059A (zh) 2018-09-25 2020-03-31 上海轶诺药业有限公司 胺基脲敏感性胺氧化酶抑制剂制备及其应用
WO2020063854A1 (zh) 2018-09-27 2020-04-02 南京明德新药研发有限公司 作为vap-1抑制剂的喹啉类衍生物
EP3856176A4 (en) 2018-09-28 2022-05-04 Acucela Inc. INHIBITORS OF VAP-1
AU2019351124A1 (en) 2018-09-28 2021-05-20 Acucela Inc. Inhibitors of VAP-1
CN112789277B (zh) 2018-10-22 2022-11-04 广东东阳光药业有限公司 胍类衍生物及其用途
EP3870162A4 (en) 2018-10-24 2022-08-24 Metacrine, Inc. SSAO INHIBITORS AND USES THEREOF
TWI835945B (zh) 2018-12-14 2024-03-21 南韓商柳韓洋行股份有限公司 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
TW202039486A (zh) 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
AU2020206477B2 (en) 2019-01-11 2022-11-10 Transthera Sciences (Nanjing), Inc. Haloallylamine compounds and application thereof

Also Published As

Publication number Publication date
JP2021518384A (ja) 2021-08-02
JP7383627B2 (ja) 2023-11-20
EP3768675B1 (en) 2026-04-01
CA3093057A1 (en) 2019-09-26
EP3768675C0 (en) 2026-04-01
CN111886233A (zh) 2020-11-03
CN111886233B (zh) 2024-01-02
WO2019180646A1 (en) 2019-09-26
KR20200124759A (ko) 2020-11-03
TWI803600B (zh) 2023-06-01
US10995086B2 (en) 2021-05-04
US20210317110A1 (en) 2021-10-14
US11780830B2 (en) 2023-10-10
JP2023145748A (ja) 2023-10-11
EP3768675A4 (en) 2021-12-22
EP3768675A1 (en) 2021-01-27
US20190322655A1 (en) 2019-10-24
TW202003508A (zh) 2020-01-16
AU2019237344B2 (en) 2023-07-06
KR102788118B1 (ko) 2025-03-31
AU2019237344A1 (en) 2020-10-01
KR20190110736A (ko) 2019-10-01

Similar Documents

Publication Publication Date Title
AR115006A1 (es) Derivados de aril o heteroaril triazolona o sales de los mismos o composiciones farmacéuticas que comprenden los mismos
AR117617A1 (es) Compuestos de sulfonilurea como inhibidores de la actividad de interleuquina 1
MX2021011606A (es) Compuestos dirigidos a prmt5.
UY38297A (es) Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos
AR115822A1 (es) Compuestos de sulfonimidamida como inhibidores de la actividad de interleuquina-1
AR114631A1 (es) Métodos e intermedios para preparar compuestos de piridina
AR114803A1 (es) Compuestos de 4-aminoisoindolin-1,3-diona sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos
DOP2020000222A (es) Derivado policiclico de piridona
PE20251594A1 (es) Derivado policiclico de carbamoilpiridona
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
MX391647B (es) Derivados heterociclicos de seis miembros y composicion farmaceutica que los comprende.
NI202000058A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
MX384474B (es) Derivado de anillo fusionado de 9 elementos.
AR110122A1 (es) Fenoxitriazoles
AR110349A1 (es) Compuestos pirazol 1,3-sustituido útiles para la reducción de los niveles de ácidos grasos de cadena muy larga
AR112900A1 (es) Compuesto derivado de pirazol y uso de este
CU20210006A7 (es) Derivados de fenil-n-quinolina y proceso para su preparación
CO2021017202A2 (es) Compuestos tricíclicos
AR043823A1 (es) Compuestos derivados de oxima, su preparacion y elaboracion de medicamentos que los contienen
PE20230182A1 (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter
DOP2022000073A (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
MX393004B (es) Derivado heterociclico nitrogenado biciclico y composicion farmaceutica que lo contiene.
AR109688A1 (es) Compuestos de indazol para uso en lesiones de tendones y/o ligamentos
AR103499A1 (es) Péptidos antagonistas de prgc
ECSP23088732A (es) Moduladores de trex1

Legal Events

Date Code Title Description
FA Abandonment or withdrawal